艾拉莫德联合甲氨蝶呤治疗难治性强直性脊柱炎疗效及对患者血清SOD、CTX-Ⅰ水平影响

Therapeutic Effect of Elamode Combined with Methotrexate on Refractory Ankylosing Spondylitis and Its Effect on SOD and CTX

目的:观察艾拉莫德联合甲氨蝶呤治疗难治性强直性脊柱炎的疗效及对患者血清超氧化物歧化酶(SOD)、Ⅰ-型胶原蛋白C末端肽(CTX-Ⅰ)的影响。方法:难治性强直性脊柱炎患者80例随机分为观察组(n=41)和对照组(n=39)。对照组给予甲氨蝶呤治疗,观察组给予艾拉莫德联合甲氨蝶呤治疗。两组疗程均为3个月。比较治疗前后两组患者的总有效率、晨僵时间、关节疼痛评分、胸廓扩张度,以及血清C反应蛋白(CRP)、红细胞沉降率(ESR)、SOD、CTX-Ⅰ水平变化,以及两组药品不良反应发生情况。结果:治疗后,观察组总有效率显著高于对照组(P<0.05)。治疗后两组晨僵时间、关节疼痛评分、胸廓扩张度,以及血清CRP、ESR、SOD、CTX-Ⅰ水平均较治疗前显著改善(P<0.05),且观察组各项指标均明显优于对照组(P<0.05)。两组药品不良反应发生率的差异无统计学意义(P>0.05)。结论:艾拉莫德联合甲氨蝶呤治疗难治性强直性脊柱炎的疗效显著,安全性好,可缓解病情进展,改善临床症状和生活质量,清除氧自由基,改善骨代谢。

Objective:To study therapeutic effect of elamode combined with methotrexate on refractory ankylosing spondylitis and its effect on superoxide dismutase(SOD)and C-terminal peptide of typeⅠcollagen(CTX-Ⅰ).Methods:Eighty patients of refractory ankylosing spondylitis were selected as research objects.According to random number table,those patients were divided into the observation group(n=41)and the control group(n=39)randomly.The control group was treated with methotrexate,while the observation group treated with elamode combined with methotrexate for 3 months.Then the therapeutic efficacy,morning stiffness time,joint pain score,C-reactive protein(CRP),erythrocyte sedimentation rate(ESR),thoracic dilatation,SOD,CTX-Ⅰlevels,adverse reactions incidence of two groups after treatment were compared.Results:After treatment,the total effective rate of observation group was significantly higher than that of control group(P<0.05).After treatment,the time of morning stiffness,joint pain score,chest expansion degree,and serum CRP,ESR,SOD,CTX-Ⅰlevels in the two groups were significantly improved compared with those before treatment(P<0.05).All the indexes in the observation group were significantly better than those in the control group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion:The therapeutic effect of eilamod combined with methotrexate in the treatment of refractory ankylosing spondylitis is significant.It can alleviate the progress of the disease,improve the clinical symptoms and quality of life,eliminate oxygen free radicals,improve bone metabolism,and is safe and effective.